The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide shortage of ADHD treatment drugs.
The newly approved medication can treat both ADHD in patients six years and older and binge-eating disorder in adults, the FDA said in an announcement.